Search results for

Achim Krebs of HGF and Filip De Corte of Syngenta provide an overview of compensatory term rights for plant protection products around the world

Min Son of Hanol IP & Law reports on South Korea’s bid to lead the way on autonomous vehicles with a streamlined patent process.

In-house at IBM, Pure Storage, Appian and HubSpot debate the value of disclosures and patent quantity in light of budgets and other challenges

Ingrid Hering, London

According to Polish law the right of protection for a trade mark lapses on failure to put it to genuine use for the goods covered by the registration for a period during five successive years, unless serious reasons of non-use exist. Preparations for the use of the trade mark are not sufficient and the five-year period begins the day after a decision on granting protection rights is issued, in case the owner has not used the trade mark, or if the trade mark had been in use, on the date its genuine use was abandoned.

Australia has hit out at procedural delays at the WTO, saying that failure to get legal certainty on the issue of plain packaging of tobacco is having a chilling effect on countries considering introducing similar measures

Five years after the entry into force of Community Regulation No 1383/03 relating to Customs control measures, it is now time to draw the initial conclusions, all positive, regarding its effectiveness. The European Commission has published, for the year 2008, data that confirm a significant increase in Customs activity:

A Community trade mark registration provides its owner with rights in each of the 27 member states, and as the EU expands those rights are extended to new member states as well.

There are an estimated 190 core biotech and 460 biotech-related companies operating in Australia Approximately 35 core biotech companies and 25 biotech-related companies are publicly listed The industry as a whole has raised about A$900 million since the previous industry report in 1999, five times more than estimated in 1998-1999 Revenues generated by core biotech companies over the past 12 months are estimated at almost A$1 billion. Human health, equipment and services, and agriculture are the sectors with the most number of products under development. In 2001 there is an estimated A$300 million of ongoing publicly funded research in biotechnology Victoria has the greatest number of core biotechnology companies (38%) New South Wales has the highest number of biotech-related companies (40%) R&D investment by Australian biotech companies in 1999-2000 was approximately A$150 million. Approximately half the biotech companies operate in the human health sector, including diagnostics and therapeutics Genomics and bio-informatics companies has more than doubled since 1999 Australia's patent system gives it a competitive advantage in attracting foreign companies to invest in the country's biotechnology industry, according to a recently released report on the growth of the sector.

Oral arguments in the DABUS appeal centred on whether the wording of UK patent law has room for an AI inventor, as Managing IP reports live from court